1 / 5

Hypertension affected an estimate of 517 million people in 2014; this figure will grow to 561 million in 2021.

Hypertension is a chronic medical condition characterized by elevated blood pressure in the arteries. It affected an estimated 517 million people in 2014, a figure that will grow at a Compound Annual Growth Rate (CAGR) of 1.2% to 561 million in 2021 in the four Asia-Pacific (APAC) regions of China, India, Australia, and Japan. This high prevalence is a substantial contributor to healthcare costs and a major cause of morbidity. Despite this, awareness of hypertension is low among physicians, patients, and the public alike, leading to poor blood pressure control.

mireports
Télécharger la présentation

Hypertension affected an estimate of 517 million people in 2014; this figure will grow to 561 million in 2021.

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Anti- hypertensive Therapeutics in Asia- Pacific Markets to 2021- Increasing Prevalence of Hypertension Drives Market Growth despite Weak Pipeline The Global Anti- hypertensive Therapeutics market is expected to increase in value at a CAGR of 1.2% from $517 million to $561 million. Click Here To Check Complete Report

  2. Summary of the Report: Hypertension is a chronic medical condition characterized by elevated blood pressure in the arteries. It affected an estimated 517 million people in 2014, a figure that will grow at a Compound Annual Growth Rate (CAGR) of 1.2% to 561 million in 2021 in the four Asia- Pacific (APAC) regions of China, India, Australia, and Japan. This high prevalence is a substantial contributor to healthcare costs and a major cause of morbidity. Despite this, awareness of hypertension is low among physicians, patients, and the public alike, leading to poor blood pressure control. The classes of drugs prescribed to treat hypertension are Angiotensin Converting Enzyme Inhibitors (ACEI), Angiotensin Receptor Blockers (ARB), Calcium Channel Blockers (CCB), beta-blockers, renin inhibitors, and diuretics. The percentage of patients treated using monotherapy and combination therapy (including fixed-dose combinations) varies from country to country. The most commonly prescribed drugs in the CCB class are amlodipine and lercanidipine, while the leading ARBs are telmisartan, candesartan, olmesartan, irbesartan, losartan, valsartan, azilsartan medoxomil, and eprosartan. Ramipril, imidapril, perindopril, enalapril, lisinopril, benazepril, fosinopril, trandolapril, and quinapril dominate the ACEIs.

  3. Scope of the Report: • Hypertension prevalence is a prominent contributor to market size in the assessed countries. The market is mostly dominated by generics, and there are only a few patented products. Will generics continue to dominate treatment? How do the elderly populations and their associated risk factors affect prevalence? The current anti-hypertensive therapeutics pipeline is weak, comprising 124 molecules in various stages of development, dominated by small molecules. Will the upcoming molecules change the treatment paradigm in the near future? How will the weak pipeline affect the market? How do failure rates vary by product stage of development, molecule type, and mechanism of action? How do other factors such as average trial duration and trial size influence the costs and risks associated with product development? Over the 2014–2021 forecast periods, the APAC anti-hypertensive therapeutics market is expected to increase in value at a CAGR of 3.4% from $15.7 billion to just over $19.9 billion. Growth is projected to vary considerably across the four assessed markets. • • • • • • • • Download Sample Brochure

  4. Reasons to Buy: • • This report will enable you to – Understand the clinical context of hypertension by considering symptoms, etiology, pathophysiology, co-morbidities and complications, epidemiology, diagnosis, and treatment options. Identify the therapeutic strategies, products, and companies that dominate the current marketed products landscape, and recognize gaps. Appreciate key anti-hypertensive pipeline trends in molecule type, administration route, mechanism of action, and novelty. Consider market opportunities and potential risks by examining trends in anti-hypertensive clinical trial size, duration, and failure rate by stage of development, molecule type, and mechanism of action. Compare treatment usage patterns, annual therapy costs, and market growth projections for the China, India, Australia, and Japan. Discover trends in licensing and co-development deals concerning anti-hypertensive products and identify the major strategic consolidations that have shaped the commercial landscape. • • • • • Make an Inquiry Before Buying

  5. Anti- hypertensive Therapeutics in Asia- Pacific Markets to 2021- Increasing Prevalence of Hypertension Drives Market Growth despite Weak Pipeline A detailed qualitative analysis of the factors responsible for driving and restraining growth of the global Anti- hypertensive Therapeutics in Major Developed Markets and future opportunities are provided in the report. Click here to order a copy of Anti- hypertensive Therapeutics Markets to 2021 Report Contact: 1-302-684-6088 sales@marketintelreports.com www.marketintelreports.com

More Related